Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA.
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Expert Opin Drug Deliv. 2024 Jun;21(6):829-843. doi: 10.1080/17425247.2024.2375400. Epub 2024 Jul 4.
Understanding the interactions between administered nanoparticles and the liver is crucial for developing safe and effective nanomedicines. As the liver can sequester up to 99% of these particles due to its major phagocytic role, understanding these interactions is vital for clinical translation.
This review highlights recent studies on nanoparticle-liver interactions, including the influence of nanoparticle physicochemical properties on delivery, strategies to enhance delivery efficiency by modulating liver Kupffer cells, and their potential for treating certain hepatic diseases. Additionally, we discuss how aging impacts the liver's phagocytic functions.
While liver accumulation can hinder nanomedicine safety and effectiveness, it also presents opportunities for treating certain liver diseases. A thorough understanding of nanoparticle-liver interactions is essential for advancing the clinical application of nanomedicines.
了解已给药的纳米颗粒与肝脏之间的相互作用对于开发安全有效的纳米药物至关重要。由于肝脏具有主要的吞噬作用，它可以隔离高达 99%的这些颗粒，因此了解这些相互作用对于临床转化至关重要。
本综述强调了最近关于纳米颗粒-肝脏相互作用的研究，包括纳米颗粒物理化学性质对递药的影响、通过调节肝枯否细胞来提高递药效率的策略，以及它们在治疗某些肝脏疾病方面的潜力。此外，我们还讨论了衰老如何影响肝脏的吞噬功能。
虽然肝脏蓄积会阻碍纳米药物的安全性和有效性，但也为治疗某些肝脏疾病提供了机会。深入了解纳米颗粒-肝脏的相互作用对于推进纳米药物的临床应用至关重要。
